OBJECTIVE: Cryoenergy is a new valuable treatment option to perform ablation close to the atrioventricular (AV) node in the cure of supraventricular tachycardias because of its favourable properties, such as the possibility of creating reversible lesions. The aim of this study was to report our experience on the effectiveness and safety of catheter cryoablation performed in "critical areas" to treat a large cohort of patients with supraventricular arrhythmias. METHODS: One hundred and thirty-one patients suffering from supraventricular tachycardias underwent catheter cryoablation using a 7F catheter. Eighty-seven patients presented with AV nodal re-entrant tachycardia (AVNRT), 39 had accessory pathways (APs) either manifest or concealed (15 midseptal, 24 parahissian), three had ectopic right atrial tachycardia (AT), and two patients had a permanent junctional reciprocating tachycardia (PJRT). When the optimal parameters were recorded, ice mapping at -30 degrees C was performed for 80 s to validate the ablation site. If the expected result occurred, cryoablation was carried out by lowering the temperature to -75 degrees C for 4 min. RESULTS: In two patients cryoablation was not performed because of technical reasons. Cryoablation was acutely successful in 84 out of 85 patients with AVNRT, in 37 of 39 with APs and in all patients with AT and PJRT. No complications occurred in any patient. Transient AV conduction impairment occurred in seven patients with midseptal APs and in two patients with AVNRT. In particular, in these patients no late permanent AV block was observed at follow-up. At a mean follow-up of 27 +/- 12.9 months, clinical success rate was 87%. CONCLUSIONS: Cryoablation is a safe and effective technique with a high success rate in the long term. It may be particularly useful when performing ablation close to the AV node or His bundle owing to the possibility of validating the ablation site with ice mapping, which creates only a reversible lesion, mainly in the midseptal APs.
OBJECTIVE: Cryoenergy is a new valuable treatment option to perform ablation close to the atrioventricular (AV) node in the cure of supraventricular tachycardias because of its favourable properties, such as the possibility of creating reversible lesions. The aim of this study was to report our experience on the effectiveness and safety of catheter cryoablation performed in "critical areas" to treat a large cohort of patients with supraventricular arrhythmias. METHODS: One hundred and thirty-one patients suffering from supraventricular tachycardias underwent catheter cryoablation using a 7F catheter. Eighty-seven patients presented with AV nodal re-entrant tachycardia (AVNRT), 39 had accessory pathways (APs) either manifest or concealed (15 midseptal, 24 parahissian), three had ectopic right atrial tachycardia (AT), and two patients had a permanent junctional reciprocating tachycardia (PJRT). When the optimal parameters were recorded, ice mapping at -30 degrees C was performed for 80 s to validate the ablation site. If the expected result occurred, cryoablation was carried out by lowering the temperature to -75 degrees C for 4 min. RESULTS: In two patients cryoablation was not performed because of technical reasons. Cryoablation was acutely successful in 84 out of 85 patients with AVNRT, in 37 of 39 with APs and in all patients with AT and PJRT. No complications occurred in any patient. Transient AV conduction impairment occurred in seven patients with midseptal APs and in two patients with AVNRT. In particular, in these patients no late permanent AV block was observed at follow-up. At a mean follow-up of 27 +/- 12.9 months, clinical success rate was 87%. CONCLUSIONS: Cryoablation is a safe and effective technique with a high success rate in the long term. It may be particularly useful when performing ablation close to the AV node or His bundle owing to the possibility of validating the ablation site with ice mapping, which creates only a reversible lesion, mainly in the midseptal APs.
Authors: Greg Morley; Scott Bernstein; Laura Kuznekoff; Carolina Vasquez; Phil Saul; Dieter Haemmerich Journal: IEEE Trans Biomed Eng Date: 2018-11-09 Impact factor: 4.538
Authors: Axel Meissner; Irini Stifoudi; Peter Weismüller; Max-Olav Schrage; Petra Maagh; Martin Christ; Thomas Butz; Hans-Joachim Trappe; Gunnar Plehn Journal: Int J Med Sci Date: 2009-01-11 Impact factor: 3.738